References

[1] Akbari M, Oryan A, Hatam G. Application of nanotechnology in treatment of leishmaniasis: A review. Acta Tropica. 2017;172:86-90

[2] Handler MZ, Patel PA, Kapila R, Al-Qubati Y, Schwartz RA.

[3] Pace D. Leishmaniasis. The Journal of Infection. 2014;69(S1):S10-S18

[4] Di Muccio T et al. Epidemiology of imported leishmaniasis in Italy: Implications for a European endemic country. PLoS ONE. 2015;10(6):1-16

[5] Antinori S, Gianelli E, Calattini S, Longhi E, Gramiccia M, Corbellino M. Cutaneous leishmaniasis: An increasing threat for travellers. Clinical Microbiology and Infection. 2005;11(5):343-346

[6] Oryan A, Akbari M. Worldwide risk factors in leishmaniasis. Asian Pacific Journal of Tropical Medicine. 2016;9 (10):925-932

[7] Alvar J et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS ONE. 2012;7(5):e35671

[8] Mohammadi MA, Bamorovat M, FasihiHarandi M, Karimi T, Sharifi I, Aflatoonian MR. Comparison of three PCR-based methods for simplicity and cost effectiveness identification of cutaneous leishmaniasis due to Leishmaniatropica. Iranian Journal of Parasitology. 2017;12(2):215-223

[9] Bates PA. Transmission of Leishmaniametacyclicpromastigotes by phlebotomine sand flies. International Journal for Parasitology. 2007;37(10):1097-1106

[10] Ready PD. Sand fly evolution and its relationship to Leishmania transmission. Memorias do Instituto Oswaldo Cruz. 2000;95(4):589-590

[11] Ready PD. Leishmaniasis emergence in Europe. Eurosurveillance. 2010;15(10):29-39

[12] Ribeiro PAF et al. Evaluation of a Leishmania hypothetical protein administered as DNA vaccine

or recombinant protein against Leishmaniainfantum infection and its immunogenicity in humans. Cellular Immunology.

[13] Leishman WB. On the possibility of the occurrence of trypanosomiasis in India. British Medical Journal. 1903;2(2238):1376-1377

[14] Gotoff SP, Esterly NB. Histiocytosis. The Journal of Pediatrics. 1 Oct 1974; 85(4):592-594

[15] Ross MR. Further notes on leishmans bodies. British Medical Journal. 1903;2(2239):1401

[16] Gokmen TG, Haytoglu S, Guran M, Kusςu F, Koksal F. A multidisciplinary approach to an uncommon case of laryngeal leishmaniasis in Turkey. Journal of Vector Borne Diseases. 2014;51(2):140-143

[17] Barroso DH, Silva CEF, e Vasconcelos ACDP, Cavalcanti SM d M, de Brito MEF, Medeiros ACR. Post-kala-azar dermal leishmaniasis in two different clinical contexts. Anais Brasileiros de Dermatologia. 2015;90(3):108-110

[18] Von Stebut E. Leishmaniasis. Journal der Deutschen Dermatologischen Gesellschaft. 2015;13(3):191-201

[19] Salam N, Al-Shaqha WM, Azzi A. Leishmaniasis in the middle East: Incidence and epidemiology. PLoS Neglected Tropical Diseases. 2014;8(10):1-8

[20] Rioux J, Jalouk L, Khiami A, Ilaboratoire CD. Evidence for a long-term Aleppo, Syria increase in the incidence of Leishmania Tropica in Aleppo, Syria. Transactions of the Royal Society of Tropical Medicine and Hygiene. 1993;87(3):247-249

[21] Lun ZR et al. Visceral leishmaniasis in China: An endemic disease under control. Clinical Microbiology Reviews. 2015;28(4):987-1004

[22] Ngouateu OB et al. Clinical features and epidemiology of cutaneous leishmaniasis and Leishmania major/ HIV co-infection in Cameroon: Results of a large cross-sectional study. Transactions of the Royal Society

of Tropical Medicine and Hygiene. 2012;106(3):137-142

[23] Bart A, van Thiel PP, de Vries HJ, Hodiamont CJ, Van Gool T. Imported leishmaniasisin the Netherlands from 2005 to 2012: Epidemiology, diagnostic techniques and sequence­based species typing from 195 patients. Eurosurveillance. 2013;18 (30)

[24] Pigott DM, Bhatt S, Golding N, et al. Global distribution maps of the leishmaniases.

[25] Roberts T et al. Molecular epidemiology of imported cases of leishmaniasis in Australia from 2008 to 2014. PLoS ONE. 2015;10 (3):1-11

[26] Kumar R, Nylen S. Immunobiology of visceral leishmaniasis. Frontiers in Immunology. 2012;3:1-10

[27] Gupta G, Oghumu S, Satoskar AR. Mechanisms of immune evasion inLeishmaniasis. Advances in Applied Microbiology. 2014;82:1-23

[28] Guimaraes-Costa AB et al. Leishmaniaamazonensispromastigotes induce and are killed by neutrophil extracellular traps. Proceedings of the National Academy of Sciences. 2009;106(16):6748-6753

[29] Lieke T, Nyln S, Eidsmo L, Schmetz C, Berg L, Akuffo H.

The interplay between Leishmaniapromastigotes and human natural killer cells in vitro leads to direct lysis of Leishmania by NK cells and modulation of NK cell activity by Leishmaniapromastigotes. Parasitology. 2011;138(14):1898-1909

[30] Thalhofer CJ, Chen Y, Sudan B, Love-Homan L, Wilson ME. Leukocytes infiltrate the skin and draining lymph nodes in response to the protozoan leishmaniainfantumchagasi. Infection and Immunity. 2011;79(1):108-117

[31] Mattner J, Donhauser N, Werner-Felmayer G, Bogdan C.

NKT cells mediate organ-specific resistance against Leishmania major infection. Microbes and Infection. 2006;8(2):354-362

[32] Rai AK, Thakur CP, Seth T,

Mitra DK. Enrichment of invariant natural killer T cells in the bone marrow of visceral leishmaniasis patients. Parasite Immunology. 2011;33(12):688-691

[33] Belkaid Y, Piccirillo CA, Mendez S. CD4+ CD25+ regulatory T cells control Leishmania major persistence and immunity, Nature, vol. 420, no.September, 2002. pp. 633-637

[34] Ansari NA, Saluja S, Salotra P. Elevated levels of interferon-γ, interleukin-10, and interleukin-6 during active disease in Indian kalaazar. Clinical Immunology. 2006;119(3):339-345

[35] Caldas A et al. Balance of IL-10 and interferon-γ plasma levels in human visceral leishmaniasis: Implications

in the pathogenesis.

[36] Ghalib HW, Ahmed M, Steven G. Interleukin 10 production correlates with pathology in human Leishmania donovani infections. Journal of Clinical Investigation. 1993;92:324-329

[37] Karp CL et al. In vivo cytokine profiles in patients with kala-azar. The Journal of Clinical Investigation. 1993;91:1644-1648

[38] Saraiva M, Christensen JR, Veldhoen M, Murphy TL, Murphy KM, O’Garra A. Interleukin-10 production by Th1 cells requires interleukin-12-induced STAT4 transcription factor and ERK MAP kinase activation by high antigen dose. Immunity. 2009;31(2):209-219

[39] Stumhofer JS et al. Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10. Nature Immunology. 2007;8(12):1363-1371

[40] Prajapati VK et al. Targeted killing of leishmaniadonovani in vivo and

in vitro with amphotericin β attached to functionalized carbon nanotubes. The Journal of Antimicrobial Chemotherapy. 2011;66 (4):874-879

[41] Gimblet C et al. IL-22 protects against tissue damage during cutaneous leishmaniasis. PLoS ONE.

2015;10 (8):1-18

[42] Holaday BJ, Sadick MD, Wang ZE, et al. Reconstitution of Leishmania immunity in severe combined immunodeficient mice using Th1-and Th2-like cell lines. The Journal of Immunology. 1 Sep 1991;147(5):1653-1658

[43] Nozzi M, Del Torto M, Chiarelli F, Breda L. Leishmaniasis and autoimmune diseases in pediatric age. Cellular Immunology. 2014;292(1):9-13

[44] Mcgwire BS, Satoskar AR. Leishmaniasis: Clinical syndromes and treatment. QJM. 2014;107(1):7-14

[45] Mansueto P, Seidita A, Vitale G, Cascio A. Leishmaniasis in travelers: A literature review. Travel Medicine and Infectious Disease. 2014;12(6):563-581

[46] Mans DR, Kent AD, Hu RVPF, Schallig HD. Epidemiological, biological and clinical aspects of Leishmaniasis with special emphasis on BusiYasi

in Suriname. Journal of Clinical and Experimental Dermatology Research. 2017;08(02):388

[47] Faleiro RJ, Kumar R, Hafner LM, Engwerda CR.

[48] Anversa L et al. Human leishmaniasis in Brazil: A general review. Revista da Associaςao Medica Brasileira. 2018;64(3):281-289

[49] Croft S, Yardley V. Chemotherapy of leishmaniasis. Current Pharmaceutical Design. 2002;8(4):319-342

[50] Mondelaers A, Hendrickx S,

Van Bockstal L, Maes L, Caljon G. Miltefosine-resistant Leishmaniainfantum strains with an impaired MT/ROS3 transporter complex retain amphotericin B susceptibility. The Journal of Antimicrobial Chemotherapy. 2017;73(2):392-394

[51] Socolsky C, Salamanca E, Gimenez A, Borkosky SA, Bardon

A. Prenylatedacylphloroglucinolswith Leishmanicidalactivity from the fern elaphoglossumlindbergii.

Journal of Natural Products. Jan. 2016;79(1):98-105

[52] Manzano JI, Garcia-Hernandez R, Castanys S, Gamarro F. A new ABC half-transporter in Leishmania major is involved in resistance to antimony. Antimicrobial Agents and Chemotherapy. 2013;57(8):3719-3730

[53] Henderson DM, Sifri CD,

Rodgers M, Wirth DF, Hendrickson N, Ullman B. Multidrug resistance in Leishmaniadonovani is conferred by amplification of a gene homologous to the mammalian mdr1 gene.

Molecular and Cellular Biology. Jun. 1992;12 (6):2855-2865

[54] Tanwar J, Das S, Fatima Z, Hameed S. Multidrug resistance: An emerging crisis. Interdisciplinary Perspectives on Infectious Diseases. 2014;2014:541340

[55] Mohapatra S. Drug resistance in leishmaniasis: Newer developments. Tropical Parasitology. 2014;4 (1):4

[56] Bruhn KW et al. Killed

but metabolically active Leishmaniainfantum as a novel whole­cell vaccine for visceral leishmaniasis. Clinical and Vaccine Immunology. 2012;19 (4):490-498

[57] Da Silva ER, Maquiaveli C d C, Magalhaes PP. The leishmanicidalflavonolsquercetin and quercitrin target Leishmania (Leishmania) amazonensisarginase. Experimental Parasitology. 2012;130(3):183-188

[58] Thakur CP et al.

[59] Carneiro SMP, Carvalho FAA, Santana LCLR, Sousa APL, Neto JMM, Chaves MH. The cytotoxic and antileishmanial activity of extracts and fractions of leaves and fruits of Azadirachtaindica (aJuss.). Biological Research. 2012;45 (2):111-116

[60] Khanna VG, Kannabiran K, Getti G. Leishmanicidal activity of saponins isolated from the leaves of Ecliptaprostrata and Gymnemasylvestre. Indian Journal of Pharmacology. 2009;41 (1):32-35

[61] Chouhan G et al. Leishmanicidal activity of Piper nigrum bioactive fractions is interceded via apoptosis in vitro and substantiated by Th1 immunostimulatory potential in vivo. Frontiers in Microbiology. 2015;6:1-19

[62] de Souza A et al. Promising nanotherapy in treating leishmaniasis. International Journal of Pharmaceutics. 2018;547(1-2):421-431

[63] Jain K, Jain NK. Novel therapeutic strategies for treatment of visceral leishmaniasis. Drug Discovery Today. 2013;18(23-24):1272-1281